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Abstract
Background: The purpose was to evaluate the overlap frequency of irritable bowel syndrome (IBS), gastroesophageal
reflux disease (GERD), and overactive bladder syndrome (OBS), as well as other gastrointestinal and systemic symptoms,
in functional dyspepsia (FD). Additionally, we sought to determine whether adult Rome III FD subtypes were uniquely
related to overlap syndromes or symptoms.
Methods: The study was a retrospective review of 100 consecutive pediatric patients, age 8–17 years, diagnosed with
FD. All had completed a standardized medical history including gastrointestinal and systemic symptoms as well
as specific symptoms related to GERD and OBS. The frequency of overlap with IBS, GERD, and OBS were determined for
the whole group and for those fulfilling adult FD subtype criteria. Individual symptoms were also compared by
FD subtype.
Results: Overlap IBS was present in 33 % of the FD patients. At least one GERD symptom was present in 74 %
of patients with 41 % reporting heartburn. At least one OBS symptom was present in 44 % of patients with 29 %
reporting urinary urgency. Other than pain, the most common reported gastrointestinal symptom was nausea
(86 %). Systemic symptoms were common. Overlap syndromes/symptoms did not vary by FD subtype. Postprandial
distress syndrome was associated with pain with eating, weight loss, and waking at night to have a stool.
Conclusions: FD is a heterogeneous condition in children and adolescents with significant variability in the presence
of gastrointestinal and non-gastrointestinal symptoms and overlap syndromes. Varying symptom profiles need to be
accounted for and analyzed in studies involving subjects with FD.
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Background
There are a number of pain-associated functional
gastrointestinal disorders (FGIDs) defined by Rome III
for children/adolescents, namely irritable bowel syn-
drome (IBS), functional dyspepsia (FD), abdominal
migraines, functional abdominal pain, and functional
abdominal pain syndrome [1]. In adults, there are two
recognized FD subtypes, postprandial distress syn-
drome (PDS; defined by the presence of early satiety
preventing completing a normal size meal or fullness
following a normal sized meal) and epigastric pain syn-
drome (EPS; defined by the presence of pain or burning
localized to the epigastrium) [2] These subtypes are not
recognized in the pediatric Rome III criteria, although
there is some evidence of their existence and indication
that the distinction may be clinically meaningful in
youth as well [3, 4]. For example, PDS-related symp-
toms (i.e., early satiety and/or bloating following a
meal) have been associated with increased mucosal
mast cells, anxiety, and depression in pediatric FD [4].
Most children and adolescents with chronic abdom-
inal pain fulfill criteria for an FGID with FD and IBS
being the two most common [1, 5, 6]. These diagnoses
form the entry criteria for most abdominal pain studies
and therapeutic trials. Utilization of these criteria for
research (or clinical practice) presents challenges given
some inherent ambiguity in the criteria, inconsistent
application of the criteria, and differences in symptom
reports between the patients and their parents or
guardians [7]. Additionally, there may be overlap be-
tween FGIDs or overlap between FGIDs and other
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symptoms or conditions which may influence study re-
sults or therapeutic response. For adults, FD is well
known to overlap with IBS, as well as other conditions
such as gastroesophageal reflux disease (GERD) and
overactive bladder syndrome (OBS) [8–11]. Overlap
syndromes may be associated with greater psychopath-
ology and electromechanical dysfunction [12, 13]. We
have previously found that FD/IBS overlap accounts for
30 % of youth presenting for initial evaluation of
chronic abdominal pain [6]. This represents another
area of variability in utilization of Rome criteria as
some investigators diagnose overlap FD/IBS while
others presumably default to IBS when symptoms of
both are present [7]. Overlap with GERD and OBS has
been largely unstudied in a pediatric population. It is
important to determine to what degree, if any, individ-
ual FGIDs overlap with other syndromes or symptoms
in order to understand variability within a diagnostic cat-
egory which may affect study results or patient outcomes.
The purpose of the current study was to evaluate the
frequency of overlap IBS, potential GERD-related symp-
toms, and OBS-related symptoms, as well as other
gastrointestinal and systemic symptoms, in a clinical
sample of youth with FD. Additionally, we sought to de-
termine the frequency of PDS and EPS in youth with
FD, and whether these subtypes were uniquely related to
overlap syndromes or other symptoms.
Methods
Study design
The current study was a retrospective chart review of
pediatric patients who were identified as being diag-
nosed with FD after being seen for initial evaluation of
chronic abdominal pain in a subspecialty abdominal pain
clinic housed within a large Midwestern children’s hos-
pital between September, 2014 and June, 2015. All data
described below were collected as part of standard care
and were abstracted from the medical record and en-
tered into a research database for analysis in the current
study. The study was approved by the institutional re-
view board at Children’s Mercy Kansas City.
Study cohort and exclusion criteria
All patients selected for inclusion had been evaluated
in a single subspecialty abdominal pain clinic. Patients
were 8–17 years, inclusive, and reported pain at least
weekly for a minimum of 8 weeks per standard entry
criteria for the clinic. The diagnosis of FD was determined
according to Rome III criteria by a single board-certified
pediatric gastroenterologist based on an extensive history
and physical examination conducted with each child and
family during the initial clinic visit [1]. All patients had
undergone upper endoscopy with biopsy after failing to
respond to acid reduction therapy of at least 2 weeks
duration. All were without gross pathology (including
nodularity, erosions, and ulceration. Per standard
protocol at the participating hospital, all patients had at
least 2 biopsies obtained from each of the lower one-
third of the esophagus and the gastric antrum and at
least four biopsies from the duodenum for histologic
evaluation. All patients were negative for Helicobacter
pylori on antral biopsy. Mild histologic esophagitis
(peak eosinophils < 5/hpf ) and/or mild chronic gastritis
did not exclude the patient from selection. Patients di-
agnosed with other pathology, including eosinophilic
gastroenteritis, celiac disease, inflammatory bowel disease,
or giardiasis, were excluded from the study cohort. Eo-
sinophilic gastritis and duodenitis were diagnosed at the
discretion of the evaluating board-certified pathologist as




As a prerequisite for inclusion in the study cohort, pa-
tients had to have previous biopsies to evaluate for the
presence of histologic esophagitis as assessed by a board
certified pediatric pathologist as part of routine care.
The pathology report provided the histologic data for
analysis.
Gastrointestinal and systemic symptoms
All patients seen for initial evaluation in the abdominal
pain clinic from which the sample was selected had
completed a standardized medical history. This medical
history included questions regarding the presence of
upper abdominal pain or discomfort, as well as any rela-
tion to a change in stool frequency or consistency or a
history of relief from stooling. In addition, specific loca-
tions of the pain were obtained by asking the patient to
mark pain locations on a diagram of the abdomen. The
nature of the pain (e.g. burning, crampy) was asked of
each patient. Patients were specifically asked whether
pain wakes them at night and whether pain increases
after a meal. Patients also were asked about the presence
of nausea and/or vomiting and whether nausea increases
after a meal. Relevant to the issue of FD subtyping, pa-
tients were asked specifically about the presence of early
satiety and postprandial bloating [2].
Patients also are asked about the presence of a number
of other gastrointestinal and systemic symptoms. Gastro-
intestinal symptoms that are assessed include the pres-
ence of stool symptoms such as loose stools, hard stools,
mucus in stools, blood in stools, and waking at night to
have a stool, as well as the presence of excessive gas.
Systemic symptoms that are assessed include hayfever,
fatigue, headache, fainting, dizziness, chest pain, muscle
pain, joint pain, mouth sores, weight loss, and fever. In
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addition to the above, patients are asked about the pres-
ence of 4 symptoms related to gastroesophageal reflux
(bitter, salty, or sour taste in mouth; excessive belching
or burping; regurgitation; heartburn) and 3 symptoms
related to overactive bladder syndrome (increased fre-
quency of urination; waking during the night to urinate;
sudden urge to urinate).
Information from the medical history, once abstracted
and entered into the research database, was used to
evaluate dyspeptic symptoms and assign an FD subtype
based on adult Rome III criteria. Patients were defined
as having postprandial distress syndrome if they en-
dorsed early satiety or postprandial bloating [2]. Patients
were defined as having epigastric pain syndrome if they
endorsed burning or pain localized only to the epigastric
region [2]. Diagnoses of potentially overlapping symp-
toms and conditions (i.e., IBS, GERD, OBS) also were
assigned based on symptom information abstracted from
the patient’s medical history.
Statistical analysis
Statistical analysis was performed using SPSS Version 20
(SPSS Inc, Chicago, IL). Frequencies were determined
for individual symptoms and diagnoses. The frequencies
of individual reflux symptoms were compared between
patients with and without mild histologic esophagitis by
chi-square analysis or Fisher’s exact tests, as appropriate
given cell frequencies. The frequencies of an IBS diagno-
sis, reflux symptoms, and overactive bladder symptoms,
respectively, were compared between genders, between
patients <13 years of age and those ≥13 years of age, and
between patients with and without PDS by chi-square
analysis or Fisher’s exact tests, as appropriate given cell
frequencies. A p value of <0.05 was considered statisti-
cally significant for all of the analyses. Given the explora-
tory nature of the current study, trends were reported
for p values >0.05 but <0.07.
Results
Demographics of the study cohort
One hundred patients ranging in age from 8 to 17 years
with a mean age of 13 years 9 months were evaluated.
Seventy-six percent were female. Pain was reported to
occur daily in 76 %, several times/week in 19 %, and
weekly in 5 % of patients. Pain was described as inter-
mittent by 60 % and continuous by 40 % of patients. For
patients reporting nausea (n = 86), the nausea occurred
daily in 36 % and at least weekly in 76 %. Sixty-three
percent reported that nausea increased with eating. Fre-
quencies of other selected gastrointestinal symptoms
and systemic symptoms are shown in Table 1. All pa-
tients had failed to respond clinically to acid reduction
therapy. Forty percent were treated with ranitidine
(>6 mg/Kg/day up to 150 mg twice daily) and 72 % were
treated with a proton pump inhibitor (PPI; >1 mg/Kg/day
up to 40 mg twice daily for omeprazole, pantoprazole, and
esomeprazole and up to 30 mg twice daily for lansopra-
zole). Twelve percent received courses of both raniti-
dine and a PPI. Of those treated with a PPI, 32 %
received twice daily dosing and 21 % received multiple
courses of different PPIs. As a requirement, all patients
underwent upper endoscopy with biopsies. No patients
had a previous upper gastrointestinal barium study,
gastric emptying study, or pH-impedance study. No pa-
tients reported previous food allergy testing and while
some patients were avoiding specific foods, none had
been on a full elimination diet.
FD subtypes
Seventy-two percent of patients met criteria for PDS.
Bloating was reported by 62 % and early satiety by 74 %
of all FD patients. Of those endorsing early satiety,
85 % reported that it prevented finishing a regular meal.
While 52 % of all patients reported epigastric pain or
burning, only 3 % localized this pain and/or burning
only to the epigastrium as required to fulfill criteria for
EPS. Twenty-five percent of patients met criteria for
FD but not PDS or EPS subtypes.
Overlap syndromes/symptoms in FD
One-third (33 %) of FD patients also fulfilled criteria for
IBS. Frequencies for GERD-related symptoms are shown
in Table 2. At least one symptom was reported by 74 %,
2 or more symptoms by 49 %, 3 or more symptoms by
29 %, and all 4 symptoms by 6 % of patients. Patients
with mild histologic esophagitis reported higher frequen-
cies compared to those with normal histology for bitter/
Table 1 Frequency of specific gastrointestinal and systemic
symptoms in FD patients
Symptom % Reporting Symptom
Waking at night with pain 64
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salty taste (52 vs. 29 %; p = .046), belching/burping (62
vs. 22 %; p = .001), regurgitation (64 vs. 54 %; p = .042),
and heartburn (71 vs. 32 %; p = .001). Frequencies for
OBS-related symptoms are shown in Table 2. Of the pa-
tients reporting night time urination, 67 % reported that
this occurred at least weekly. At least one symptom was
reported by 44 %, 2 or more symptoms by 23 %, and all
3 symptoms by 8 %. No differences were found in the
frequencies of overlap relative to age or gender with one
exception. Specifically, IBS overlap was more common
in females 13 years of age and older as compared to
younger females (36 vs. 13 %; p = .037).
Overlap syndromes/symptoms by FD subtype
Patients fulfilling criteria for PDS (as compared to those
who did not) were more likely to report pain with eating
(79 vs. 43 %; p = .001), weight loss (36 vs. 14 %; p = .026),
and waking at night to have a stool (27 vs. 7 %; p = .025).
There also were trends for patients with PDS to be more
likely to report nausea with eating (70 vs. 50 %; p = .052),
pain relief with a stool (39 vs. 21 %; p = .069), mucus in
the stool (17 vs. 4 %; p = .067), and increased gas (44 vs.
25 %; p = .066). Although other gastrointestinal and sys-
temic symptoms were found to be relatively common in
the broader group of patients with FD, no other correla-
tions emerged between these symptoms and the PDS
subtype. PDS also did not have any significant associa-
tions with any GERD-related or OBS-related symptoms.
Associations with overlap syndromes/symptoms were
not examined for EPS given the low base rate (3 %) in
the study cohort.
Discussion
The current study indicates that FD is a heterogeneous
condition in children and adolescents. There is signifi-
cant variability in the presence of gastrointestinal, as
well as non-gastrointestinal, symptoms. It is important
to understand this variability within diagnostic categor-
ies, and also within individual patients as each patient
appears to have a somewhat unique symptom profile
within the broad category of FD.
Overlap IBS was present in 33 % of the FD patients in
the current study. Previously we found IBS overlap in
54 % of patients fulfilling FD criteria [6]. Consistent with
these pediatric findings, IBS overlap has been reported
in 33–56 % of adults with FD [14–16]. In adults, IBS oc-
curs more often in those with FD (37 %) as compared to
those without FD (7 %) [12]. IBS has been found to be
more common with the PDS subtype in some, but not
all, studies in adults [12, 15]. We found no association
between overlapping IBS and PDS; however, the PDS
subtype patients were more likely to report the individ-
ual symptom of waking at night to have a stool. There
was also a trend towards increased reporting of pain im-
provement with a stool in the PDS subgroup. Associa-
tions with EPS could not be assessed given the low EPS
frequency. In adults, FD/IBS overlap patients were more
likely to be female. (13) We did not find any main effect
of gender in our pediatric cohort, however, females
13 years of age and older were more likely to report
overlap than were younger females (12 years of age and
under).
Evaluating for the presence of GERD overlap in youth
with FD presents a challenge, as there is no gold stand-
ard test for GERD. Symptoms and available tests lack
high sensitivity or specificity. However, the North
American Society for Pediatric Gastroenterology, Hepa-
tology, and Nutrition guidelines concluded, based on ex-
pert opinion, that the diagnosis of GERD can be made in
adolescents with typical heartburn symptoms [17].
Heartburn is considered to be a reasonably sensitive in-
dicator of GERD in adults [18]. Heartburn was reported
by 41 % of the patients in the current study. Although a
definitive statement isn’t possible, our data suggest that
reflux-like symptoms are common in youth with FD.
The correlation between reflux-like symptoms and mild
histologic esophagitis adds some support for these symp-
toms being related to GERD in at least some patients.
Reported prevalence of GERD in adults with FD has
ranged from 13.3 to 56 %, with the prevalence being
near 50 % in most studies [12]. This overlap appears to
be greater in those patients with non-erosive GERD
(NERD) and, within this group, overlap is greatest
among those with heartburn [8, 9]. It has been suggested
that heartburn should be considered an integral part of
the dyspepsia complex in adults [19].
Overactive bladder symptoms were common in FD pa-
tients in the current study, with at least one symptom
present in 44 %. In adults, OAB is defined as a symptom
complex of urinary urgency usually with urinary fre-
quency and nocturia [10]. The hallmark of OAB in chil-
dren is urgency. (20) In the current study, urgency was
reported by 29 % of the patients. This is similar to the
Table 2 Frequency of overlap syndromes and symptoms in FD
patients
Syndrome/Symptom % of patients
IBS 33
GERD: bitter, salty, or sour taste 35
GERD: excessive belching or burping 30
GERD: regurgitation 57
GERD: heartburn 41
OBS: increased frequency of urination 13
OBS: waking at night to urinate 33
OBS: sudden urge to urinate 29
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20.5 % prevalence of OAB in adults with FD [11]. Patho-
physiologic processes implicated in OAB are similar to
those that appear relevant to FD (and IBS) including
nerve hypersensitivity and mucosal mast cells [20–22].
The FD subtypes, PDS and EPS, are well recognized in
adults but were not included in the pediatric FD criteria
[1]. In adults, some studies have shown good separation
of PDS and EPS while others have reported significant
overlap of the two subtypes [23]. It appears that separ-
ation is better in the general population than in patients
who seek medical care [24]. In one pediatric study,
Turco and colleagues evaluated 100 pediatric patients
with FD and found EPS alone in 17 %, PDS alone in
47 %, and overlap in 36 %; however, many of these pa-
tients crossed over their diagnosis between PDS and EPS
over time [3]. In the current study, 72 % of our pediatric
cohort met criteria for PDS, while only 3 % met criteria
for EPS. Similar to our previous findings regarding EPS,
52 % of the patients in the current study reported epi-
gastric pain or burning, but only 3 % localized this pain
exclusively to the epigastrium, a requirement for diag-
nosing EPS under the Rome III adult criteria [4].
Adult data suggests that meal-related symptoms, in-
cluding pain and nausea, may be the norm in FD [25].
The PDS subtype did have some associations with other
GI symptoms in our pediatric cohort, including in-
creased pain with eating (79 %) and weight loss (36 %),
as well as a trend toward increased nausea with eating
(70 %). Thus, the consequences of eating may be more
widespread than just early satiety. In adult studies, nau-
sea has been reported by 39–65 % of FD patients [24].
Overall, nausea was reported by 86 % of pediatric pa-
tients in the current study with 70 % reporting an
increase in nausea with eating. In another pediatric ab-
dominal pain study, nausea was reported by 87 % of
subjects who met adult criteria for FD [26]. Thus, nau-
sea appears to be a common component of FD in both
adults and youth. However, nausea may be more associ-
ated with PDS than EPS in children [3]. Nausea is im-
portant to consider as it is associated with poor school
functioning and greater social disability [26]. These
meal related symptoms may also be associated with nu-
tritional consequences. As noted above, weight loss was
common in the current study being reported by 36 % of
PDS patients. This is similar to adults where weight loss
correlates most strongly with early satiety [27].
The main strength of the current study is the rela-
tively large population size with symptom reporting
performed in a standardized fashion across a wide array
of gastrointestinal and non-gastrointestinal symptoms.
The main limitation is that the study design did not allow
evaluation of the natural history of these symptoms. It is
known that symptoms may evolve across time and pa-
tients may change FD subtype classification [3].
Conclusions
In sum, pediatric FD is a heterogeneous syndrome exhi-
biting variable symptoms from patient to patient with
many, but not all, fulfilling criteria for PDS. The clinical
presentation of FD also varies with regard to non-FD
symptoms, exhibiting significant overlap with IBS as
well as symptoms consistent with GERD and OBS.
These varying symptom profiles need to be considered
in providing care to FD patients. For example, an FD
patient with overlap may have a different pathogenic
process or respond differently to a treatment regimen
than a patient with FD alone or FD with overlap GERD.
Likewise, varying symptom profiles need to be accounted
for and analyzed in studies involving subjects with FD.
Clinical trials need to be designed to fit the patients that
are actually encountered, rather than the clean diagnostic
boxes we create.
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